GLP-1 Market
LLY $1123.00 ▼ -0.1% NVO $44.01 ▼ -1.2% PFE $27.65 ▼ -0.5% VKTX $32.13 ▼ -1.7% KLRA $14.91 ▲ +0.5% GPCR $39.55 ▼ -4.1% RHHBY $53.19 ▼ -0.4% HIMS $27.44 ▼ -1.6% WW $14.78 ▼ -1.1%
Delayed · As of 9:20 AM

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

GW869682

Company
GlaxoSmithKline
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Trial details
  • Completed NCT NCT00291356

    GSK189075, GW869682 Or Placebo In Type 2 Diabetic Patients

    Not yet reported GlaxoSmithKline 45 participants Est. completion 2006-05 3 sites
    Type 2 diabetes Other conditions: Non-Insulin-Dependent Diabetes Mellitus
    View official trial listing →
  • Completed NCT NCT00297180

    Weight Loss In Obese Subjects Taking Either GW869682 Or Placebo 3 Times Per Day For 12 Weeks

    Not yet reported GlaxoSmithKline 136 participants Est. completion 2006-09 3 sites
    Other conditions: Obesity
    View official trial listing →
  • Completed NCT NCT00494767

    Investigation Of Weight Loss And Body Composition Changes After Dosing With Either Placebo Or One Of Two Active Drugs

    Not yet reported GlaxoSmithKline 27 participants Est. completion 2007-06-07 1 site Stand-alone
    Type 2 diabetes Other conditions: Obesity
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.